

## SUPPORTING INFORMATION

### Novel selective inhibitors of the plasmodial zinc aminopeptidase M1 as potential antimalarial agents.

Marion Flipo<sup>a</sup>, Terence Beghyn<sup>a</sup>, Virginie Leroux<sup>a</sup>, Isabelle Florent<sup>b</sup>, Benoit P. Deprez<sup>a</sup>, Rebecca F. Deprez-Poulain<sup>a</sup>.

- a. Inserm, U761, Lille, F-59006 France ; Univ Lille2, Faculté Pharmacie Lille, F-59006 France ; Institut Pasteur Lille, « Biostructures and Drug Discovery », Lille, F-59019 France.  
b. USM504/EA3335 Muséum National d'Histoire Naturelle ; « Regulations, Development, Molecular diversity » Paris, F-75005 France.

#### Table of Contents:

**S2** : Table of purities for target compounds, analyzed by 2 different HPLC techniques.

**S3**: Inhibition results at 10 µM of PfA-M1 and APN for each member of the library.

Stereochemical assignments for **65**, **66** and **68** (**S4** to **S7**) :

**S4**: <sup>1</sup>H NMR spectrum and excerpt of <sup>13</sup>C non decoupled <sup>1</sup>H spectrum of compound **65**.

**S5**: <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of compound **66**.

**S6**: Excerpt of HSQC and ROESY NMR spectra of compound **66**.

**S7**: Comparison of analytical data of compound **68** to those of compound **66**.

**Table of purities for target compounds, analyzed by 2 different HPLC techniques.**

<b>Compound</b>	Method 1 <sup>a</sup>		Method 2 <sup>b</sup>	
	<b>t<sub>R</sub>1</b>	<b>Purity (215nm)</b>	<b>t<sub>R</sub>2</b>	<b>Purity (215 nm)</b>
<b>32</b>	3.90	100	1.24	100
<b>33</b>	4.11	100	1.75	100
<b>34</b>	4.63	100	2.40	100
<b>37</b>	4.71	100	2.57	100
<b>38</b>	4.13	95	1.38	100
<b>39</b>	4.74	95	2.14	100
<b>40</b>	5.03	95	2.92	100
<b>41</b>	5.32	100	6.29	100
<b>42</b>	5.47	99	8.20	100
<b>43</b>	5.90	99	19.44	100
<b>44</b>	6.26	99	14.32	100
<b>47</b>	5.82	99	17.44	100
<b>48</b>	6.05	99	26.44	100
<b>49</b>	4.25	100	1.47	100
<b>50</b>	4.31	100	1.95	100
<b>51</b>	4.82	98	2.95	100
<b>52</b>	5.20	99	5.15	100
<b>53</b>	4.92	99	2.34	100
<b>54</b>	5.46	95	8.27	97
<b>55</b>	3.16	96	1.57	100
<b>56</b>	4.53	100	2.29	97
<b>57</b>	4.31	100	1.67	100
<b>58</b>	4.80	97	2.69	100
<b>59</b>	4.53	97	2.02	100
<b>60</b>	4.89	99	3.75	95
<b>61</b>	5.45	99	8.62	100
<b>62</b>	5.43	99	8.14	95
<b>63</b>	5.49	98	8.23	100
<b>66</b>	4.23	99	1.42	100
<b>68</b>	4.41	99	1.98	99
<b>71</b>	5.10	99	2.90	100
<b>72</b>	6.01	99	8.90	96


<sup>a</sup> HPLC analysis was performed on a LCMS-MS triple-quadrupole system (Varian 1200ws) using a C18 TSK-GEL Super ODS 2 µm particle size column, dimensions 50 \* 4.6 mm. A gradient starting from 100% H<sub>2</sub>O / 0.1% formic acid and reaching 20% H<sub>2</sub>O / 80% CH<sub>3</sub>CN / 0.08% formic acid within 10 min at a flow rate of 1 mL/min was used.

<sup>b</sup> HPLC analysis was performed on a HPLC (Shimadzu SP-10A) using a C18 ACE 3 µm particle size column, dimensions 50 \* 4.6 mm. The analysis was performed under isocratic conditions (70% sodium acetate buffer 10 mM pH=5 adjusted with glacial acetic acid / 30 % acetonitrile) within 30 min at a flow rate of 1.5 mL/min.

**Inhibition results at 10 µM of PfA-M1 and APN for each member of the library**


R <sub>1</sub>	NH <sub>2</sub>	H	m-PhO-benzyl	i-butyl	benzyl	NH <sub>2</sub>	H	m-PhO-benzyl	i-butyl	benzyl	
Amine	PfA-M1 (% inhibition at 10 µM)						APN (% inhibition at 10 µM)				
<b>1</b>	10	2	96	19	94	77	19	79	39	69	
<b>2</b>	5	10	96	90	93	54	13	76	99	80	
<b>3</b>	9	6	35	85	91	18	16	22	92	72	
<b>4</b>	6	1	102	24	67	55	40	84	45	75	
<b>5</b>	-6	3	99	-4	-6	24	18	85	30	15	
<b>6</b>	9	32	99	88	95	23	17	86	98	85	
<b>7</b>	-1	-4	86	23	45	29	9	89	37	36	
<b>8</b>	-8	-2	98	74	82	25	27	88	105	70	
<b>9</b>	-7	-2	67	30	29	22	16	85	86	47	
<b>10</b>	20	-2	43	61	26	36	12	72	93	61	
<b>11</b>	2	0	66	42	59	16	14	78	93	76	
<b>12</b>	64	2	93	98	94	8	15	89	95	84	
<b>13</b>	56	19	96	87	94	42	36	84	92	81	
<b>14</b>	12	-4	80	2	76	10	11	95	20	53	
<b>15</b>	37	22	36	42	45	-1	45	52	60	28	
<b>16</b>	2	-3	41	58	43	37	19	86	86	28	
<b>17</b>	3	22	77	66	67	18	32	83	81	46	
<b>18</b>	-4	-2	5	3	3	25	14	72	57	21	
<b>19</b>	-2	-9	38	38	20	11	11	63	103	46	
<b>20</b>	49	-3	100	74	84	32	19	84	90	50	
<b>21</b>	-3	7	97	21	53	23	11	31	19	29	
<b>22</b>	18	8	84	29	75	-5	23	47	28	21	
<b>23</b>	45	7	97	100	92	39	23	65	68	34	
<b>24</b>	-6	5	65	7	40	43	19	70	26	22	
<b>25</b>	12	6	74	15	-1	34	19	76	54	56	
<b>26</b>	-4	-5	48	16	7	9	27	81	21	32	
<b>27</b>	8	50	50	76	65	62	87	59	102	83	
<b>28</b>	4	5	38	42	75	34	32	67	105	56	
<b>29</b>	-5	21	-6	-2	0	10	14	41	19	14	
<b>30</b>	35	28	41	69	71	62	66	81	95	90	
<b>31</b>	51	44	68	88	87	31	55	69	96	83	

**<sup>1</sup>H NMR spectrum and excerpt of <sup>13</sup>C non decoupled <sup>1</sup>H spectrum of compound 65**




The  $^{13}\text{C}$  non decoupled  $^1\text{H}$  NMR experiment was used for determining  $^1\text{H}-\text{C}=\text{C}-^{13}\text{C}$  coupling constants of compound **65**. The *trans* coupling constant of alkenes is always larger than the corresponding *cis* coupling constant. This experiment allows thus to attribute an *E* configuration to compound **65**.

**<sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of compound 66**



The J-modulated <sup>13</sup>C NMR experiment is useful to differentiate primary and tertiary carbons (that are above the spectrum) from secondary and quaternary carbons (that are under the spectrum).

## Excerpt of HSQC and ROESY NMR spectra of compound 66



ROESY NMR spectrum shows that H<sub>4</sub> interacts with the hydrogen of the amide function thus these two proton are close in space. This allows us to attribute a Z configuration to compound **66**.

### Comparison of analytical data of compound **68** to those of compound **66**

**66** and **68**, were obtained from the same intermediate **65** by reversing the sequence of introduction of amine and protected hydroxylamine. Comparison of  $^1\text{H}$  NMR spectra and LC chromatograms proves that compounds **68** and **66** are two isomers respectively *E* and *Z*.

